P2RY12 and coronary artery disorder: Though there is evidence that diabetes patients with established coronary artery disease may gain benefits of reduced ischaemic risk from long-term DAPT compared to aspirin alone [33, 34], there is currently no evidence for use of P2Y12 inhibitors for primary prevention of cardiovascular events in any population, including in those with diabetes.